U
UNIQURE NV
NASDAQ: QURE (uniQure N.V.)
Last update: 5 hours ago30.84
4.69 (17.93%)
| Previous Close | 26.15 |
| Open | 26.49 |
| Volume | 6,044,061 |
| Avg. Volume (3M) | 4,126,050 |
| Market Cap | 1,921,074,944 |
| Price / Earnings (Forward) | 27.93 |
| Price / Sales | 94.24 |
| Price / Book | 2.83 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -2,815.25% |
| Diluted EPS (TTM) | -4.38 |
| Quarterly Revenue Growth (YOY) | -81.50% |
| Total Debt/Equity (MRQ) | 1,522.46% |
| Current Ratio (MRQ) | 11.99 |
| Operating Cash Flow (TTM) | -166.25 M |
| Levered Free Cash Flow (TTM) | -122.89 M |
| Return on Assets (TTM) | -15.64% |
| Return on Equity (TTM) | -241.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | uniQure N.V. | Bearish | Bullish |
AIStockmoo Score
-0.7
| Analyst Consensus | 1.0 |
| Insider Activity | -3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.70 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.09% |
| % Held by Institutions | 91.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rtw Investments, Lp | 30 Jun 2025 | 5,158,231 |
| Ecor1 Capital, Llc | 30 Jun 2025 | 3,988,971 |
| Vestal Point Capital, Lp | 30 Jun 2025 | 3,700,000 |
| Avoro Capital Advisors Llc | 30 Jun 2025 | 3,625,000 |
| Jefferies Financial Group Inc. | 30 Jun 2025 | 2,095,931 |
| Sofinnova Investments, Inc. | 30 Jun 2025 | 1,558,356 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Guggenheim, 208.04%) | Buy |
| Median | 62.50 (102.66%) | |
| Low | 38.00 (Goldman Sachs, 23.22%) | Hold |
| Average | 64.60 (109.47%) | |
| Total | 9 Buy, 1 Hold | |
| Avg. Price @ Call | 40.68 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 11 Nov 2025 | 53.00 (71.85%) | Buy | 29.38 |
| 03 Nov 2025 | 53.00 (71.85%) | Buy | 34.29 | |
| Leerink Partners | 10 Nov 2025 | 60.00 (94.55%) | Buy | 26.15 |
| 24 Sep 2025 | 68.00 (120.49%) | Buy | 47.50 | |
| Goldman Sachs | 04 Nov 2025 | 38.00 (23.22%) | Hold | 30.44 |
| 25 Sep 2025 | 56.00 (81.58%) | Hold | 52.65 | |
| HC Wainwright & Co. | 04 Nov 2025 | 70.00 (126.98%) | Buy | 30.44 |
| 06 Oct 2025 | 110.00 (256.68%) | Buy | 52.91 | |
| RBC Capital | 04 Nov 2025 | 45.00 (45.91%) | Buy | 30.44 |
| Wells Fargo | 02 Oct 2025 | 80.00 (159.40%) | Buy | 54.50 |
| 25 Sep 2025 | 65.00 (110.77%) | Buy | 52.65 | |
| Cantor Fitzgerald | 25 Sep 2025 | 80.00 (159.40%) | Buy | 52.65 |
| Guggenheim | 25 Sep 2025 | 95.00 (208.04%) | Buy | 52.65 |
| Mizuho | 25 Sep 2025 | 60.00 (94.55%) | Buy | 52.65 |
| Stifel | 24 Sep 2025 | 65.00 (110.77%) | Buy | 47.50 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KAYE JACK | - | 30.44 | -38,810 | -1,181,376 |
| Aggregate Net Quantity | -38,810 | |||
| Aggregate Net Value ($) | -1,181,376 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 30.44 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KAYE JACK | Director | 04 Nov 2025 | Automatic sell (-) | 38,810 | 30.44 | 1,181,376 |
| KAYE JACK | Director | 04 Nov 2025 | Option execute | 38,810 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |